![]() |
市場調查報告書
商品編碼
1433294
全球自體傷口貼片市場 2023-2030Global Autologous Wound Patches Market 2023-2030 |
全球自體傷口貼片市場在預測期內(2023-2030)預計將以 9.2%的CAGR成長。自體傷口貼片為患者提供了新的治療選擇,因為它們有助於加速傷口癒合並降低併發症的風險。全身皮膚損傷持續擾亂數百萬患者的日常生活,導致住院時間延長、感染和死亡。傷口癒合設備的進步改善了臨床實踐,但主要集中在治療宏觀癒合而不是潛在的微觀病理生理學。使用一系列傷口癒合產品的最佳治療策略缺乏共識,這推動了新療法的設計。
全球自體傷口貼片市場依類型、應用程式和最終用戶進行細分。依類型,市場分為富血小板血漿和富血小板纖維蛋白。根據應用,市場分為急性傷口和慢性傷口。根據最終用戶,市場分為醫院、診所和門診手術中心。在該類型中,富含血小板的纖維蛋白細分市場預計將佔據相當大的市場佔有率,因為它的旋轉速度較低,這使得一些白血球和幹細胞能夠保持完整因此,富含血小板的纖維蛋白斑塊中存在更多的癒合因子,有助於慢性傷口更快的癒合。
其中,慢性傷口細分市場預計將在全球自體傷口貼片市場中佔據相當大的佔有率。該細分生長歸因於多種因素,例如慢性傷口、先進繃帶針對失調的發炎階段、替換皮膚組織並防止感染。在糖尿病傷口中,最近的注意力集中在透過誘導急性發炎來啟動癒合過程。肥大細胞穩定劑的預防性遞送和神經肽 P 物質的釋放都會在糖尿病小鼠受傷後誘導強烈的炎症,改善傷口上皮再形成,並加速傷口癒合。根據世界衛生組織統計,全球約有 4.22 億人患有糖尿病,其中大多數生活在低收入和中等收入國家,每年有 150 萬人死亡直接歸因於糖尿病。在過去的幾十年裡,糖尿病的病例數和盛行率都在穩定增加。
全球自體傷口貼片市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,亞太地區預計將在全球市場中佔據顯著佔有率,因為該地區道路和創傷事故數量不斷增加,導致複雜傷口患者數量增加。自體傷口貼片特別適合治療此類傷口,因為它們可以幫助促進組織再生並輕鬆修復損傷。
在所有地區中,歐洲地區預計在預測期內將以相當大的CAGR成長。區域成長歸功於該地區的醫療進步和創新。人們越來越關注開發新型和創新的自體傷口貼片,這些貼片具有改進的特性,例如更快的癒合時間、減少的疼痛和不適以及易於使用。例如,2023年7月,RedDress(由患者自己的全血創建的個人化自體傷口護理解決方案)宣布,其ActiGraft PRO 產品現已在美國各地上市,並且有資格透過NCD 270.3 從Medicare 和Medicare Advantage 獲得全國範圍內的償付以及 G-0465 和 G-0460 代碼。它使醫療保健提供者能夠從患者自己的血液中「即時」產生體外血塊。一旦使用,血塊就會充當保護層並支持身體的自然傷口癒合反應。它可用於各種難以治療的慢性傷口,包括糖尿病足潰瘍、壓力性損傷、靜脈性潰瘍、外傷傷口和手術後傷口。
服務自體傷口貼片市場的主要公司包括 Reapplix、PRP Concepts、RedDress、Nuo Therapeutics 等。市場參與者透過各種策略(包括併購、夥伴關係、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2023年8月,ActiGraft PRO 系統(一種由患者自己的全血創建的個人化自體傷口護理解決方案)的開發商RedDress 宣布,其ActiGraft PRO 產品現已透過美國最大的提供者驅動的醫療保健Vizient 提供績效改善公司。此外,它還宣布與 Asker Healthcare Group 旗下的 OneMed 建立策略合作夥伴關係,在芬蘭各地商業化和分銷 ActiGraft 系統。
Global Autologous Wound Patches Market Size, Share & Trends Analysis Report by Type (Platelet Rich Plasma and Platelet Rich Fibrin), by Application (Acute wound and chronic wound), and by End-User (Hospitals, Clinics, and Ambulatory Surgical Center), Forecast Period (2023-2030)
The global autologous wound patches market is anticipated to grow at a CAGR of 9.2% during the forecast period (2023-2030). Autologous wound patches offer new treatment option for patients, as they can help to accelerate wound healing and reduce the risk of complications. Skin injuries across the body continue to disrupt everyday life for millions of patients and result in prolonged hospital stays, infection, and death. Advances in wound healing devices have improved clinical practice but have mainly focused on treating macroscale healing versus underlying microscale pathophysiology. Consensus is lacking on optimal treatment strategies using a spectrum of wound healing products, which has motivated the design of new therapies.
The global autologous wound patches market is segmented on the type, application, and end-user. Based on the type, the market is sub-segmented into platelet rich plasma and platelet rich fibrin. Based on application, the market is sub-segmented into acute wound and chronic wound. Based on the end-user, the market is sub-segmented into a hospitals, clinics, and ambulatory surgical center. Among the type, the Platelet rich fibrin sub-segment is anticipated to hold a considerable share of the market, owing to factor which includes, it spun at a lower speed, which allows some of the white blood cells & stem cells to remain intact with the platelet layer, as a result, more healing factors are present in platelet rich fibrin patches, which supports faster healing of chronic wounds.
Among the application, the chronic wound sub-segment is expected to hold a considerable share of the global Autologous wound patches market. This segmental growth is attributed to several factor such as, chronic wounds, advanced bandages target the dysregulated inflammatory phase, replace skin tissue, and protect against infection. In diabetic wounds, recent attention focused on jump-starting the healing process by inducing acute inflammation. The preventive delivery of a mast cell stabilizer and the release of the neuropeptide substance P both induced strong inflammation after wounding, improved wound re-epithelialization, and accelerated wound healing in diabetic mice. According to World health organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
The global autologous wound patches market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to Increasing number of road and traumatic accidents in the region, leading to a rise in the number of patients with complex wounds. Autologous wound patches are particularly suitable for treating these types of wounds, as they can help to promote tissue regeneration and repair the damage easily.
Among all regions, the European regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to medical advancements and innovation in the region. There is a growing focus on developing new and innovative autologous wound patches with improved properties such as faster healing times, reduced pain and discomfort, and ease of use. For instance, In July 2023, RedDress, a personalized and autologous wound care solution created from patients own whole blood, announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. it enables health care providers to produce, 'in real time' in vitro blood clots from a patient's own blood. Once applied, the blood clot serves as a protective covering and supports the body's natural wound healing response. it can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds and post-surgical wounds.
The major companies serving the autologous wound patches market include Reapplix, PRP Concepts, RedDress, Nuo Therapeutics, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2023, RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. Additionally, it announced also established a strategic partnership with OneMed, part of the Asker Healthcare Group, to commercialize and distribute the ActiGraft system throughout Finland.